| 48.845 -0.075 (-0.15%) | 11-29 11:02 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 62.58 | 1-year : | 66.3 |
| Resists | First : | 53.58 | Second : | 56.77 |
| Pivot price | 50.05  |
|||
| Supports | First : | 48.41 | Second : | 40.28 |
| MAs | MA(5) : | 49.22  |
MA(20) : | 50.55 |
| MA(100) : | 57.8 |
MA(250) : | 64.9 |
|
| MACD | MACD : | -1.6 |
Signal : | -1.6 |
| %K %D | K(14,3) : | 12.1 |
D(3) : | 15.8 |
| RSI | RSI(14): 34.1 |
|||
| 52-week | High : | 81.44 | Low : | 48.41 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ BMY ] has closed above bottom band by 25.6%. Bollinger Bands are 1.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 49.34 - 49.67 | 49.67 - 49.94 |
| Low: | 48.18 - 48.5 | 48.5 - 48.77 |
| Close: | 48.44 - 48.97 | 48.97 - 49.41 |
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Wed, 29 Nov 2023
BMY Factor-Based Stock Analysis - Nasdaq
Tue, 28 Nov 2023
Avidity Biosciences Announces Expansion of Cardiovascular ... - PR Newswire
Mon, 27 Nov 2023
What do the Fundamentals Predict for Bristol-Myers Squibb Co (BMY) Stock? - InvestorsObserver
Sun, 26 Nov 2023
Should You Be Impressed By Bristol-Myers Squibb Company's (NYSE:BMY) ROE? - Simply Wall St
Mon, 20 Nov 2023
Bristol Myers Squibb and 2seventy bio Provide Update on U.S. FDA ... - Bristol-Myers Squibb
Mon, 20 Nov 2023
Bristol Myers Squibb, 2seventy bio shares fall as FDA delays action ... - Morningstar
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers—General
|
|
| Shares Out | 2,030 (M) |
| Shares Float | 2,030 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 78.2 (%) |
| Shares Short | 23,400 (K) |
| Shares Short P.Month | 31,590 (K) |
| EPS | 3.94 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 14.26 |
| Profit Margin | 18.4 % |
| Operating Margin | 19.1 % |
| Return on Assets (ttm) | 5.5 % |
| Return on Equity (ttm) | 26.8 % |
| Qtrly Rev. Growth | -2.3 % |
| Gross Profit (p.s.) | 17.92 |
| Sales Per Share | 22.13 |
| EBITDA (p.s.) | 9 |
| Qtrly Earnings Growth | 24 % |
| Operating Cash Flow | 12,910 (M) |
| Levered Free Cash Flow | 12,520 (M) |
| PE Ratio | 12.43 |
| PEG Ratio | -26.3 |
| Price to Book value | 3.43 |
| Price to Sales | 2.21 |
| Price to Cash Flow | 7.7 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|